BIGT.L vs. GNOM.L
BIGT.L (L&G Pharma Breakthrough UCITS ETF) and GNOM.L (Global X Genomics & Biotechnology UCITS ETF) are both Health & Biotech Equities funds - BIGT.L tracks the NASDAQ Biotechnology TR USD while GNOM.L tracks the Global X Genomics & Biotechnology UCITS ETF. Both are passively managed. Over the past 3 years, BIGT.L returned 9.77%/yr vs 3.46%/yr for GNOM.L. A 0.71 correlation means they provide meaningful diversification when combined. BIGT.L charges 0.49%/yr vs 0.50%/yr for GNOM.L.
Performance
BIGT.L vs. GNOM.L - Performance Comparison
Loading charts...
Different Trading Currencies
BIGT.L is traded in GBp, while GNOM.L is traded in USD. To make them comparable, the GNOM.L values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, BIGT.L achieves a 7.76% return, which is significantly lower than GNOM.L's 21.80% return.
BIGT.L
- 1D
- -1.28%
- 1M
- 7.11%
- 6M
- 6.84%
- YTD
- 7.76%
- 1Y
- 33.20%
- 3Y*
- 9.77%
- 5Y*
- 3.20%
- 10Y*
- —
GNOM.L
- 1D
- 0.00%
- 1M
- 10.90%
- 6M
- 15.21%
- YTD
- 21.80%
- 1Y
- 61.34%
- 3Y*
- 3.46%
- 5Y*
- —
- 10Y*
- —
BIGT.L vs. GNOM.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
BIGT.L L&G Pharma Breakthrough UCITS ETF | 7.76% | 27.03% | -3.16% | -14.88% | 2.68% | -2.81% |
GNOM.L Global X Genomics & Biotechnology UCITS ETF | 21.80% | 10.80% | -16.55% | -10.48% | -29.74% | -8.05% |
Correlation
The correlation between BIGT.L and GNOM.L is 0.72, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.72 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.69 |
Correlation (All Time) Calculated using the full available price history since Nov 2, 2021 | 0.71 |
The correlation between BIGT.L and GNOM.L has been stable across timeframes, ranging from 0.69 to 0.72 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIGT.L vs. GNOM.L — Risk / Return Rank
BIGT.L
GNOM.L
BIGT.L vs. GNOM.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF (BIGT.L) and Global X Genomics & Biotechnology UCITS ETF (GNOM.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIGT.L | GNOM.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.39 | ||
| Sortino ratioReturn per unit of downside risk | -0.51 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.34 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.33 | 3.66 | -0.33 |
| Martin ratioReturn relative to average drawdown | 9.47 | 9.16 | +0.31 |
Loading charts...
Drawdowns
BIGT.L vs. GNOM.L - Drawdown Comparison
The maximum BIGT.L drawdown since its inception was -36.84%, smaller than the maximum GNOM.L drawdown of -67.55%. Use the drawdown chart below to compare losses from any high point for BIGT.L and GNOM.L.
Loading charts...
Drawdown Indicators
| BIGT.L | GNOM.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -36.84% | -67.55% | +30.71% |
Max Drawdown (1Y)Largest decline over 1 year | -9.93% | -16.99% | +7.06% |
Max Drawdown (3Y)Largest decline over 3 years | -28.44% | -45.06% | +16.62% |
Max Drawdown (5Y)Largest decline over 5 years | -30.23% | — | — |
Current DrawdownCurrent decline from peak | -6.64% | -36.84% | +30.20% |
Average DrawdownAverage peak-to-trough decline | -17.21% | -43.90% | +26.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.50% | 6.80% | -3.30% |
Volatility
BIGT.L vs. GNOM.L - Volatility Comparison
The current volatility for L&G Pharma Breakthrough UCITS ETF (BIGT.L) is 6.49%, while Global X Genomics & Biotechnology UCITS ETF (GNOM.L) has a volatility of 8.45%. This indicates that BIGT.L experiences smaller price fluctuations and is considered to be less risky than GNOM.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIGT.L | GNOM.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.49% | 8.45% | -1.96% |
Volatility (6M)Calculated over the trailing 6-month period | 14.29% | 21.47% | -7.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.03% | 29.21% | -10.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.46% | 32.06% | -10.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.23% | 32.06% | -8.83% |
BIGT.L vs. GNOM.L - Expense Ratio Comparison
BIGT.L has a 0.49% expense ratio, which is lower than GNOM.L's 0.50% expense ratio.
Dividends
BIGT.L vs. GNOM.L - Dividend Comparison
Neither BIGT.L nor GNOM.L has paid dividends to shareholders.
Frequently Asked Questions
BIGT.L and GNOM.L have a correlation of 0.72, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BIGT.L is cheaper at 0.49% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BIGT.L is cheaper with a 0.49% expense ratio, compared with 0.50% for GNOM.L.
BIGT.L tracks NASDAQ Biotechnology TR USD, while GNOM.L tracks Global X Genomics & Biotechnology UCITS ETF. They also come from different issuers: Legal & General and Global X. Their fees differ too: 0.49% for BIGT.L and 0.50% for GNOM.L.
Find the right allocation for BIGT.L and GNOM.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer